MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.
A549 Cells
Cadherins
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Fanconi Anemia
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Homeodomain Proteins
/ genetics
Humans
Lung Neoplasms
MicroRNAs
/ genetics
Signal Transduction
/ genetics
Up-Regulation
/ genetics
Zinc Finger E-box Binding Homeobox 2
/ genetics
Zinc Finger E-box-Binding Homeobox 1
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 02 2021
24 02 2021
Historique:
received:
28
12
2019
accepted:
09
02
2021
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
15
12
2021
Statut:
epublish
Résumé
The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expected to be more sensitive to cross-link based therapy or PARP inhibitors. To evaluate downstream effectors of the FA pathway, we studied the expression of 734 different micro RNAs (miRNA) using NanoString nCounter miRNA array in two FA defective lung cancer cells and matched control cells, along with two lung tumors and matched non-tumor tissue samples that were deficient in the FA pathway. Selected miRNA expression was validated with real-time PCR analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibits cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. miRNA-200C was increased in the FA defective lung cancers as compared to controls. AmpliSeq analysis showed significant reduction in ZEB1 and ZEB2 mRNA expression. Our findings indicate the miRNA-200C potentially play a very important role in FA pathway downstream regulation.
Identifiants
pubmed: 33627769
doi: 10.1038/s41598-021-83884-9
pii: 10.1038/s41598-021-83884-9
pmc: PMC7904768
doi:
Substances chimiques
Cadherins
0
Homeodomain Proteins
0
MicroRNAs
0
Zinc Finger E-box Binding Homeobox 2
0
Zinc Finger E-box-Binding Homeobox 1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4420Subventions
Organisme : NCI NIH HHS
ID : R01 CA152101
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA181291
Pays : United States
Références
Int J Cancer. 2010 Jul 15;127(2):313-20
pubmed: 19921694
Cell Commun Signal. 2017 Oct 10;15(1):41
pubmed: 29017571
Mol Med Rep. 2016 Apr;13(4):3349-55
pubmed: 26935975
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Clin Cancer Res. 2009 Aug 15;15(16):5060-72
pubmed: 19671845
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Nat Genet. 2003 Oct;35(2):165-70
pubmed: 12973351
Genes Dev. 2008 Apr 1;22(7):894-907
pubmed: 18381893
Biochem Biophys Res Commun. 2015 Oct 16;466(2):180-5
pubmed: 26343459
J Clin Invest. 2017 Aug 1;127(8):3013-3027
pubmed: 28691929
Adv Cancer Res. 2017;135:1-24
pubmed: 28882219
J Reprod Dev. 2016 Jun 17;62(3):225-34
pubmed: 26853522
PLoS One. 2014 Jul 08;9(7):e101899
pubmed: 25003366
Asian Pac J Cancer Prev. 2019 Jun 01;20(6):1633-1639
pubmed: 31244281
Oncotarget. 2017 Jul 03;8(39):65457-65468
pubmed: 29029445
Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49
pubmed: 27145721
Mol Cancer. 2014 Jul 06;13:166
pubmed: 24997798
Mol Oncol. 2012 Dec;6(6):590-610
pubmed: 23102669
PLoS One. 2017 Jul 20;12(7):e0180844
pubmed: 28727734
Oncol Rep. 2018 Jan;39(1):91-100
pubmed: 29138864
Hum Mol Genet. 2015 Sep 15;24(18):5093-108
pubmed: 26085575
Mol Cell. 2006 Aug;23(4):589-96
pubmed: 16916645
Mol Cell. 2017 Jun 1;66(5):622-634.e8
pubmed: 28575658
Genes (Basel). 2017 Mar 03;8(3):
pubmed: 28273813
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56
pubmed: 24492836
Med Oncol. 2015 Jan;32(1):428
pubmed: 25502084
J Clin Invest. 2016 Sep 1;126(9):3580-4
pubmed: 27500492
Cell Rep. 2017 Jun 20;19(12):2432-2440
pubmed: 28636932
J Mol Med (Berl). 2016 Jun;94(6):629-44
pubmed: 27094812
Oncotarget. 2014 Jan 15;5(1):185-95
pubmed: 24368337
Ann Surg Oncol. 2014 Jan;21(1):133-8
pubmed: 24046106
Blood Rev. 2017 May;31(3):93-99
pubmed: 27760710
Gene. 2016 Nov 30;593(2):265-71
pubmed: 27432063
Nat Rev Genet. 2007 Oct;8(10):735-48
pubmed: 17768402
Front Cell Dev Biol. 2017 Sep 22;5:86
pubmed: 29018797
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Virchows Arch. 2014 Oct;465(4):463-71
pubmed: 25124149
Mol Cell. 2005 Feb 4;17(3):331-9
pubmed: 15694335
J Natl Cancer Inst. 2016 Feb 04;108(7):
pubmed: 26848151
Cell Cycle. 2004 Feb;3(2):179-81
pubmed: 14712086
Cell Biosci. 2020 Mar 16;10:39
pubmed: 32190289
Curr Protoc Mol Biol. 2011 Apr;Chapter 25:Unit25B.10
pubmed: 21472696
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
J Biol Chem. 2002 Nov 29;277(48):46243-7
pubmed: 12361951
Transl Res. 2013 Mar;161(3):156-64
pubmed: 23063585
Mol Cell. 2017 Jun 1;66(5):610-621.e4
pubmed: 28575657
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Front Oncol. 2014 Dec 19;4:368
pubmed: 25566506
J Med Genet. 2016 Oct;53(10):672-680
pubmed: 27208205
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8866-71
pubmed: 18579786
Int J Oncol. 2013 Aug;43(2):548-60
pubmed: 23708087
Cell. 2007 Apr 20;129(2):289-301
pubmed: 17412408